Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies

Epidermoid Carcinoma of the Upper Aerodigestive Tract (CEVADS) is the 6th most common cancer worldwide. Despite current therapies (radiotherapy, surgery and chemotherapy), cancers of the Upper Aerodigestive Tract (UAT) have a poor prognosis, with a 10-year survival rate of no more than 20%. For recurrent or metastatic CEVADS, the therapeutic arsenal, based for many years on chemotherapy and anti-EGFR (Epidermal Growth Factor Receptor) agents, has been enriched by a new therapeutic class: PD-1 inhibitors. For CEVADS, PD-1 inhibitors have been approved for second-line treatment of nivolumab for

Trial Details

NCT ID

NCT06061705

Phase

NA

Sponsor

Fondation Hôpital Saint-Joseph

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

• Tumor Biopsy

Locations (sample)

• Paris, France|48.85341,2.3488
• Paris, France|48.85341,2.3488
• Paris, France|48.85341,2.3488

Key Eligibility Criteria

• Patients aged ≥ 18 years
• Patients with histologically confirmed CEVADS involving the oral cavity, oropharynx, hypopharynx or larynx
• Pre-treated patients with a first recurrence (locoregional or metastatic) who are candidates for immunotherapy
• Patient affiliated to a health insurance plan

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →